Recent 8-K filings for NMRA

• August 14, 2026, 7:13 AM ET leadership materiality 0.75 positive item 2.02item 5.02item 9.01 ◈ executive_change

  Neumora appoints Joshua Pinto as CEO, narrows Q2 net loss to $43.1M

  Joshua Pinto named CEO and Board member; Paul Berns becomes Executive Chair, effective Aug 14, 2026.

• July 27, 2026, 7:07 AM ET regulatory materiality 0.60 positive item 8.01item 9.01

  Neumora Therapeutics reports favorable NMRA-215 toxicology results, plans IND in Q4 2026

  Repeat 13-week rat toxicology study (162 animals) showed no unexpected adverse findings, resolving prior concerns from a study with 5 of 142 animals affected.

• June 15, 2026, 8:15 AM ET other material materiality 0.85 negative item 1.01item 2.03item 2.05item 7.01item 8.01item 9.01 ◈ Material Agreements◈ Restructurings & Charges

  Neumora discontinues navacaprant after Phase 3 MDD failures; cuts workforce 35%

  Navacaprant failed primary endpoint in KOASTAL-2 (p=0.813) and KOASTAL-3 (p=0.480); development discontinued.

• May 7, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Neumora Q1 net loss $53.5M, cash $147M; navacaprant data on track for Q2 2026

  Net loss of $53.5M for Q1 2026, improved from $68.0M in Q1 2025.

• March 30, 2026, 7:59 PM ET other material materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Neumora FY2025 net loss $236.9M; NMRA-511 positive data; NMRA-215 delayed to Q1 2027; cash to Q3 2027

  Cash $182.5M; FY net loss $236.9M; R&D $176.1M, G&A $60.1M; cash runway into Q3 2027.

• January 5, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  NMRA-511 Phase 1b shows clinically meaningful effect in AD agitation; navacaprant readout in Q2 2026

  NMRA-511 Phase 1b: 15.7-point mean CMAI reduction, no somnolence/sedation; plan higher doses and Phase 2/3 in 2026

• November 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Neumora Q3 net loss $56.8M; cash $171.5M; pipeline updates on NMRA-215, M4 PAMs, NMRA-511

  Net loss of $56.8M for Q3 2025 vs $72.5M in Q3 2024; R&D expense down to $40.5M from $60.6M.

• October 27, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Neumora reports NMRA-215 preclinical data: up to 19% monotherapy weight loss, 26% with semaglutide

  NMRA-215 showed class-leading 19% weight loss as monotherapy with semaglutide-like induction in DIO mice.

• October 27, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Neumora starts Phase 1 study of second M4 PAM, NMRA-898; no convulsions in preclinical

  Initiated Phase 1 SAD/MAD study of NMRA-898, an M4 positive allosteric modulator for schizophrenia and neuropsychiatric disorders.

• August 6, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Neumora Q2 net loss $52.7M, cash $217.6M; advances NMRA-861 Phase 1, obesity lead for NMRA-215

  Cash, equivalents and marketable securities of $217.6M as of June 30, 2025; expected to fund operations into 2027.

• May 30, 2025, 7:59 PM ET other material materiality 0.70 neutral item 5.07

  Neumora Therapeutics stockholders elect directors, approve option repricing and reverse split at 2025 annual meeting

  Elected Alaa Halawa (105,795,914 votes for) and Maykin Ho (114,262,481 votes for) as Class II directors.

• May 16, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Neumora receives Nasdaq minimum bid price deficiency notice; has until Nov 10, 2025 to cure

  Nasdaq notified Neumora on May 14, 2025 that its stock failed to meet the $1.00 minimum bid price requirement.

• May 12, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Neumora Q1 net loss $68M, secures $125M venture debt; navacaprant Ph3 data in 2026

  Net loss $68.0M in Q1 2025, up from $53.7M in Q1 2024; R&D expense $52.2M (incl. $6.3M final Amgen costs).

• March 3, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Neumora modifies KOASTAL-2/-3 MDD studies, delays data to 2026; R&D head departs

  KOASTAL-2/-3 paused, resume March 2025; topline data from KOASTAL-3 in Q1 2026 and -2 in Q2 2026.

• February 21, 2025, 6:59 PM ET leadership materiality 0.75 neutral item 5.02 ◈ executive_change ×2

  Neumora Therapeutics appoints Paul Berns as Chairman & CEO, Gosebruch exits

  Henry Gosebruch separates as CEO; receives 12-month base salary, 2025 target bonus, 18-month COBRA, 2024 bonus, and 12-month option exercise period.

• February 13, 2025, 6:59 PM ET leadership materiality 0.75 neutral item 5.02item 7.01item 9.01 ◈ executive_change ×8

  Founder Berns becomes CEO as Gosebruch departs; option repricing approved

  Paul L. Berns transitions from executive chair to CEO & chairman, effective Feb 14, 2025.

• January 2, 2025, 6:59 PM ET other material materiality 0.85 negative item 8.01item 9.01

  Neumora's Phase 3 KOASTAL-1 study of navacaprant fails primary endpoint in MDD

  Primary endpoint MADRS total score change at Week 6: -12.5 for both navacaprant and placebo (p=0.993); no statistical improvement.

• August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Neumora Q2 net loss $58.7M; Phase 3 MDD data on track for Q4 2024

  Cash $371.6M as of June 30, 2024, expected to fund operations into 2026.

• May 7, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Neumora Q1 net loss $53.7M; navacaprant Phase 3 MDD data on track for Q4 2024; NMRA-266 clinical hold with FDA

  Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.

• April 15, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 8.01

  Neumora's NMRA-266 Phase 1 placed on clinical hold by FDA after rabbit convulsion data

  FDA placed clinical hold on NMRA-266 Phase 1 trial due to preclinical convulsions in rabbits.

• September 19, 2023, 7:59 PM ET other material materiality 1.00 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  Neumora Therapeutics closes IPO: 14.71M shares at $17, gross proceeds ~$250.1M

  Completed IPO of 14,710,000 shares of common stock at $17.00 per share on September 19, 2023.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.65 · Most common event other_material

7 positive 5 negative 21 neutral

source · NMRA on sec.gov